![Richard Marshak](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Richard Marshak
Corporate Officer/Principal bei TRISALUS LIFE SCIENCES, INC.
Vermögen: 195 117 $ am 31.05.2024
Aktive Positionen von Richard Marshak
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TRISALUS LIFE SCIENCES, INC. | Corporate Officer/Principal | 10.08.2023 | - |
Nephraegis Therapeutics, Inc.
![]() Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics is a biopharmaceutical company based in Lake Forest, IL. Nephraegis Therapeutics, Inc. focuses on targeting acute kidney injury (AKI) through the development of a family of proprietary drug candidates. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The company was founded by Richard B. Marshak, and Bryan F. Cox has been the CEO since 2018. | Direktor/Vorstandsmitglied | 01.09.2018 | - |
Gründer | 01.09.2018 | - | |
Corporate Officer/Principal | 01.09.2018 | - |
Karriereverlauf von Richard Marshak
Ehemalige bekannte Positionen von Richard Marshak
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
LF Consulting
![]() LF Consulting Miscellaneous Commercial ServicesCommercial Services LF Consulting specializes in data management and analysis. The private company is based in Sherwood, OR. The company's services include obtaining, transforming, processing, and visualizing data to help clients make informed decisions. | Präsident | 01.01.2013 | 01.06.2022 |
Mount TAM Biotechnologies, Inc.
![]() Mount TAM Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Mount TAM Biotechnologies, Inc. is a biopharmaceutical company, which engages in the development of therapeutic products for targeting systemic lupus erythematosus ("SLE"). It also focuses in the discovery and development of novel mTOR inhibitors, with specific emphasis on developing compounds with unique mTORC1:mTORC2 inhibitory profiles. The company was founded by Chester P. Aldridge in November 2011 and is headquartered in Burlington, VT. | Direktor/Vorstandsmitglied | 01.03.2016 | 01.10.2019 |
Vorstandsvorsitzender | 01.03.2016 | 01.10.2019 | |
ABBOTT LABORATORIES | Corporate Officer/Principal | 01.01.1999 | 01.01.2013 |
Ausbildung von Richard Marshak
The University of Chicago Booth School of Business | Masters Business Admin |
University of Pennsylvania | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Operativ
Corporate Officer/Principal | 3 |
Director/Board Member | 2 |
Chief Executive Officer | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ABBOTT LABORATORIES | Health Technology |
TRISALUS LIFE SCIENCES, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Mount TAM Biotechnologies, Inc.
![]() Mount TAM Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Mount TAM Biotechnologies, Inc. is a biopharmaceutical company, which engages in the development of therapeutic products for targeting systemic lupus erythematosus ("SLE"). It also focuses in the discovery and development of novel mTOR inhibitors, with specific emphasis on developing compounds with unique mTORC1:mTORC2 inhibitory profiles. The company was founded by Chester P. Aldridge in November 2011 and is headquartered in Burlington, VT. | Health Technology |
LF Consulting
![]() LF Consulting Miscellaneous Commercial ServicesCommercial Services LF Consulting specializes in data management and analysis. The private company is based in Sherwood, OR. The company's services include obtaining, transforming, processing, and visualizing data to help clients make informed decisions. | Commercial Services |
Nephraegis Therapeutics, Inc.
![]() Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics is a biopharmaceutical company based in Lake Forest, IL. Nephraegis Therapeutics, Inc. focuses on targeting acute kidney injury (AKI) through the development of a family of proprietary drug candidates. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The company was founded by Richard B. Marshak, and Bryan F. Cox has been the CEO since 2018. | Health Technology |
- Börse
- Insiders
- Richard Marshak
- Erfahrung